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Interleukin-7 promotes survival and cell cycle progression of T-cell
acute lymphoblastic leukemia cells by down-regulating the
cyclin-dependent kinase inhibitor p27kip1
Joao T. Barata, AngeloA. Cardoso, Lee M. Nadler, and VassilikiA. Boussiotis
In normal T-cell development interleu-
kin-7 (IL-7) functions as an antiapoptotic
factor by regulating bcl-2 expression in
immature thymocytes and mature T cells.
Similar to what occurs in normal imma-
ture thymocytes, prevention of spontane-
ous apoptosis by IL-7 in precursor T-cell
acute lymphoblastic leukemia (T-ALL)
cellscorrelateswithup-regulationofbcl-2.
IL-7 is also implicated in leukemogenesis
because IL-7 transgenic mice develop
lymphoid malignancies, suggesting that
IL-7 may regulate the generation and ex-
pansion of malignant cells. This study
shows that in the presence of IL-7, T-ALL
cells not only up-regulated bcl-2 expres-
sion and escaped apoptosis but also pro-
gressed in the cell cycle, resulting in
sequential induction of cyclin D2 and
cyclin A. Down-regulation of p27kip1 was
mandatory for IL-7–mediated cell cycle
progression and temporally coincided
with activation of cyclin-dependent ki-
nase (cdk)4 and cdk2 and hyperphospho-
rylation of Rb. Strikingly, forced expres-
sion of p27kip1 in T-ALL cells not only
prevented cell cycle progression but also
reversed IL-7–mediated up-regulation of
bcl-2 and promotion of viability. These
results show for the ﬁrst time that a
causativelinkbetweenIL-7–mediatedpro-
liferation and p27kip1 down-regulation ex-
ists in malignant T cells. Moreover, these
results suggest that p27kip1 may function
as a tumor suppressor gene not only
because it is a negative regulator of cell
cycle progression but also because it is
associated with induction of apoptosis of
primary malignant cells. (Blood. 2001;98:
1524-1531)
© 2001 by TheAmerican Society of Hematology
Introduction
InnormalT-celldevelopmentinterleukin-7(IL-7)playsanonredun-
dant role as an antiapoptotic factor by regulating bcl-2 expression
in immature thymocytes and mature T cells.1 Mice deﬁcient in IL-7
receptor (IL-7R) are lymphopenic because of a defect in cell
expansion at an early stage of differentiation, and the few mature T
cells that develop are functionally impaired.2 Both defects are
completely rescued by overexpression of the antiapoptotic bcl-2
gene.3,4 Similarly, mice deﬁcient in IL-7 exhibit an early defect in
lymphopoiesis, and developmental transition of their immature
thymocytes to a T-cell committed fate is accompanied by a striking
loss of Bcl-2 protein expression and an increased proportion of
cells in G0/G1 stage of the cell cycle.5,6 Culture of immature
thymocytes from IL-7–deﬁcient mice with IL-7 caused up-
regulation of bcl-2 protein and cell survival, indicating that, during
T-cell lineage developmental transition and prior to T-cell antigen
receptor rearrangement, IL-7–mediated signals are linked to an
antiapoptosis mechanism and cell cycle progression.6
T-cell acute lymphoblastic leukemia (T-ALL) results from
clonal expansion of hemopoietic progenitors that have undergone
malignant transformation at distinct stages of differentiation, and
they may retain certain features of their normal counterparts.
Indeed earlier studies determined that similar to normal immature
thymocytes, leukemic blasts from a number of patients withT-ALL
express functional IL-7Rs.7 Subsequently, it was reported that IL-7
was stimulatory on blast colony formation and DNA synthesis,
suggesting that IL-7 may play an important regulatory role in the
biology of T-ALL.7,8 More recently, it was determined that IL-7
prevents spontaneous apoptosis of pre–T-ALL cells and this effect
correlates with up-regulation of bcl-2.9 IL-7 is produced in the bone
marrow and the thymic stroma, and, thus, it is present in the
microenvironments in which the malignant T cells develop.
Importantly, IL-7 has also been implicated in leukemogenesis
because IL-7–transgenic mice develop lymphoid malignancies.1
Therefore, the question arises whether IL-7 is involved not only in
promotion of viability but also in clonal expansion of T-ALL cells.
In the present study we show that, during culture with IL-7,
primary T-ALL cells not only escaped apoptosis but also pro-
gressed to the S1G2/M phase of the cell cycle. IL-7 induced
sequential expression of cyclin D2 and cyclin A and dramatically
increased the enzymatic activity of cyclin-dependent kinases (cdks)
cdk4, cdk6, and cdk2. This event temporally correlated with
hyperphosphorylation of Rb and progression to the S phase of the
cell cycle. Among the cip/kip and INK family cdk inhibitors, only
p27kip1 was dramatically decreased at the time of cdk2 activation
and S phase progression. Down-regulation of p27kip1 had a
causative role in IL-7–mediated cell cycle progression, because
forced sustained expression of p27kip1 prevented activation of cdk2,
hyperphosphorylation of Rb, and cell cycle progression. Impor-
tantly, viability studies revealed that forced sustained expression of
p27kip1 during culture with IL-7 not only prevented cell cycle
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reversed the effect of IL-7 on the promotion of viability. Thus, our
results show that IL-7 mediates both bcl-2 expression, leading to
prevention of apoptosis, and cell cycle progression by down-
regulating p27kip1 cdk inhibitor in primary T-ALLcells.
Materials and methods
Primary T-ALL samples and immunophenotypic analysis
T-ALL cells were obtained from the peripheral blood and/or the bone
marrow of patients with high leukemia involvement (85%-100%).
Informed consent and approval by the institutional review board was
obtained for all sample collections. Samples were enriched by density
centrifugation over Ficoll-Hypaque and then washed twice in RPMI-
1640 supplemented with 10% (vol/vol) fetal bovine serum (FBS) and 2
mM L-glutamine (further referred to as RPMI-10 media). Expression of
cell surface molecules was determined by direct labeling using standard
methodology.10 Fc receptors were blocked by incubation with mouse
immunoglobulin before the addition of the speciﬁc monoclonal antibod-
ies (mAbs). The mAbs used were ﬂuorescein isothiocyanate (FITC)-
conjugated anti-CD3 and anti-CD2 and phycoerythrin (PE)-conjugated
anti-CD4, CD5, CD7, as well as anti-CD8, CD19, CD13, and CD33.
Irrelevant isotype-matched antibodies were used as negative controls.
Samples were analyzed in a Coulter Elite or XLﬂow cytometer, and data
were acquired in listmode ﬁles. At least 5000 positive events were
measured for each sample.
In vitro culture
Cells isolated by density centrifugation over Ficoll-Hypaque were cultured
in 24-well plates as 2 3 106 cells/mL at 37°C with 5% CO2 in RPMI-10
without any cytokine (medium alone) or with 10 ng/mL IL-7 (Endogen,
Woburn, MA). At the indicated time points, cells were harvested and
processed as indicated in the following descriptions for assessment of
viability, cell cycle progression, and preparation of lysates for Western
blotting and immunoprecipitation.
Proliferation assays
Cells were cultured in ﬂat-bottom 96-well plates as 2 3 106 cells/mL at
37°C with 5% CO2 in RPMI-10 without any cytokine or with 10 ng/mL
IL-7 for the indicated time points. Cells were incubated with 3H-thymidine
(27 3 1023 mBq/well) for 16 hours prior to harvest. DNA synthesis, as
measured by 3H-thymidine incorporation, was assessed using a liquid
scintillation counter. Proliferation index was calculated as thymidine
incorporation of IL-7–cultured cells over thymidine incorporation of
medium-alone cultured cells.
Assessment of cell viability
Quantitative determination of viability of the malignant cells after
culture under different conditions was performed by using an Annexin
V-based apoptosis detection kit and the manufacturer’s protocol (R&D
Systems, Flanders, NJ). Brieﬂy, cells were suspended in the appropriate
binding buffer, stained with FITC-conjugatedAnnexin V and propidium
iodide at room temperature for 15 minutes, and subsequently analyzed
by ﬂow cytometry.
Cell cycle analysis
Determination of the percentage of cells at each stage of the cell cycle
was performed by assessment of DNA content after staining with
propidium iodide as described before.11 Brieﬂy, 5 3 105 cells per sample
were resuspended in 0.5 mL phosphate-buffered saline (PBS) and then
ﬁxed with ice-cold 80% ethanol. Propidium iodide was added at a ﬁnal
concentration of 2.5 mg/mL, ribonucleaseAwas added at 50 mg/mL, and
samples were incubated for 30 minutes at 37°C in the dark. Flow
cytometric analysis was performed by using Lysis II (Becton Dickinson,
Mountain View, CA) and/or XL2 software, and analysis of cell cycle
histograms was carried out using ModFit LT (Verity, Topsham, ME) or
WinCycle DNA Analysis software (Phoenix Flow Systems, San Di-
ego, CA).
Determination of malignant origin of IL-7–responsive cells
To determine the clonality of IL-7–responsive cells 2 approaches were
undertaken. In the ﬁrst approach, cells from patients for which
patient-speciﬁc T-cell receptor (TCR) rearrangements were identiﬁed
were cultured with IL-7. After 72 hours of culture S1G2/M cells were
sorted by ﬂow-activated cell sorter (FACS) using Hoechst 33342 dye
(Sigma-Aldrich, St Louis, MO), and the presence of speciﬁc rearrange-
ment was examined by reverse transcriptase-polymerase chain reaction
(RT-PCR) as previously described.12 PCR products were electropho-
resed through 2% agarose gels containing ethidium bromide and
visualized under UV light. Normal T cells and cells from other T-ALL
patients were used as negative controls. In the second approach, for
patients without speciﬁc rearrangements but with low or negative CD3
expression, cells were cultured with IL-7. After 72 hours of culture,
absence of CD3 expression of cells in S1G2/M was assessed by ﬂow
cytometry, using propidium iodide and FITC-conjugated CD3 (Pharmin-
gen, San Diego, CA).
Intracellular staining
Expression of Bcl-2 protein family members, Bcl-2, Bcl-xL, Bax, and
Bad was assessed at 72 hours of culture by intracellular staining. Cells
were ﬁxed in 0.1% formaldehyde for 30 minutes at 4°C, washed in PBS,
and resuspended in 13 Perm/Wash Solution (Pharmingen). The antibod-
ies used were mouse monoclonal FITC-conjugated anti–Bcl-2 (DAKO,
Glostrup, Denmark) and Bad (Transduction Laboratories, Lexington,
KY), and rabbit polyclonal puriﬁed anti–Bcl-xL (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) and Bax (Transduction Laboratories). FITC-
conjugated goat antirabbit (Southern BiotechnologyAssociates, Birming-
ham, AL) was used as secondary antibody. Irrelevant isotype-matched
antibodies were used as negative controls. Propidium iodide was added
to each sample to distinguish live from apoptotic cells. Samples were
analyzed by ﬂow cytometry (XL2 software; Beckman-Coulter, Fuller-
ton, CA). Results were expressed as the ratio of mean ﬂuorescence
intensity (MFI) of the speciﬁc antibody stain over the MFI of the
negative control antibody.
Immunoblotting, immunoprecipitation, and in vitro
kinase reactions
Following the indicated conditions and time intervals of culture, cell
lysates were prepared, and equal amounts of protein (50 mg/sample)
were analyzed by 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE), transferred onto nitrocellulose mem-
branes, and immunoblotted with the indicated mAbs or antiserum.
CyclinA, cyclin D2, cyclin E, cdk2, cdk4, cdk6, and p16INK4a antiserum
were purchased from Santa Cruz Biotechnology, p21cip1 mAb from
Upstate Biotechnology (Lake Placid, NY), and p27kip1 mAb from
Transduction Laboratories. To examine the phosphorylation status of
Rb, proteins were analyzed by 6% SDS-PAGE, transferred onto
nitrocellulose membrane, and blotted with Rb-speciﬁc mAb (Pharmin-
gen). After immunoblotting with mAbs or antiserum, immunodetection
was performed by incubation with horseradish peroxidase-conjugated
anti–mouse immunoglobulin g (IgG; 1:5000) or anti–rabbit IgG (1:
10 000; Promega, Madison, WI) as indicated by the host origin of the
primary antibody and developed by chemiluminescence (Amersham
Pharmacia Biotech, Piscataway, NJ). Stripping and reprobing of the
immunoblots were done as described.13
For in vitro kinase reactions, immunoprecipitations were done by using
equal amounts of protein (200 mg/sample) with anti-cdk2–speciﬁc anti-
serum agarose conjugate (Santa Cruz Biotechnology). In vitro kinase
reactions were performed by using histone H1 (Sigma) as exogenous
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with anti-cdk4–speciﬁc antiserum, in vitro kinase reactions were performed
by using Rb–glutathione-S-transferase (Santa Cruz Biotechnology) as
exogenous substrate as described.14 Reactions were analyzed by 10%
SDS-PAGE, transferred to polyvinylidene ﬂuoride (PVDF) membrane, and
exposed to x-ray ﬁlm.
Rapamycin and VP22/p27kip1 fusion protein
Rapamycin was purchased from Sigma-Aldrich and was added in the
culture at a ﬁnal concentration of 100 nM. VP22 fusion proteins allow
expression of recombinant proteins in cells without directly transfecting
them.15 Forced expression of exogenous p27kip1 was achieved by using a
VP22/p27kip1 fusion protein produced in COS cells as previously de-
scribed.16 Because VP22/p27kip1 fusion protein is tagged with 63 histidine,
it allows preparation of puriﬁed fusion protein from cell lysates of COS
transfectants by the use of nickel-chelated agarose columns (Pierce,
Rockford, IL). Cells were cultured as described earlier with or without IL-7
plusVP22/p27kip1 orVP22 control (1:10 vol/vol) and/or 100 nM rapamycin.
Bcl-2 antisense oligonucleotides
Bcl-2 antisense and scrambled control oligonucleotides (Biomol Research
Laboratories, Plymouth Meeting, PA) were added to the culture at 100 nM
as a complex with Lipofectin (Life Technologies [Gibco], Gaithersburg,
MD), according to a method adapted from the manufacturer’s protocol.
Brieﬂy, cells were washed twice in AIM V serum-free medium, cultured in
24-well plates, and immediately spun down. Oligonucleotides were resus-
pended in sterile double-distilled H2O and incubated for 15 minutes with
Lipofectin and AIM V medium at room temperature, before adding to the
cell culture. As an additional control sterile ddH2O was used without any
oligonucleotide. Cells with oligonucleotide mix were incubated at 37°C for
4 hours. The cells were harvested, washed, and recultured in RPMI with
10% FCS with the same concentration of oligonucleotide mix as previously
used. Bcl-2 protein expression, viability, and proliferation were assessed at
72 hours of culture.
Results
IL-7 promotes viability of T-ALL cells by up-regulating
bcl-2 protein expression
Highly enriched leukemic cells were isolated from the bone
marrow or peripheral blood of pediatric patients with T-ALL. Of
the 21 patients analyzed, all were positive for the pan–T-cell
marker CD7 as well as for CD2 and/or CD5. Eight patients were
CD32 and the remaining had a more mature phenotype and
expressed this marker on the surface. On the basis of these ﬁndings,
patients were classiﬁed according to the maturation stage of the
malignant T cells17 (Table 1). No expression of the B-lineage
differentiation antigen CD19 or the myeloid lineage markers CD13
and CD33 was detected (data not shown). Responsiveness of
leukemic cells to IL-7 was determined by inhibition of spontaneous
apoptosis during in vitro culture. Ten of 12 patients studied had a
signiﬁcant response to IL-7 as determined by increased viability
assessed by annexin V and propidium iodide staining followed by
FACS analysis, as shown in Figure 1. The effect of IL-7 in
promotion of viability was obvious at 24 hours of culture, and
maximal difference in viability between media and IL-7 cultures
was observed at 72 hours. Dose-response curves in responding
samples indicated that concentration of 10 ng/mL provided the
saturating amount of IL-7 required to induce maximal response.
Therefore, all subsequent experiments were performed at this time
interval, using the optimal concentration of IL-7.
Analysis of Bcl-2, Bcl-xL, Bad, and Bax protein expression by
ﬂow cytometry revealed that all proteins were detected in primary
T-ALL cells (data not shown). Culture with IL-7 increased Bcl-2
expression as determined by the increase in MFI compared with
culture with media alone (Table 2), a ﬁnding consistent with
previous results.9 In contrast, no changes in bcl-xL, bad, or bax
expression correlated with culture in IL-7 and IL-7–mediated
Table 1. Immunophenotype, classiﬁcation, and response to IL-7 of 21 patients with T-ALL
Patients CD2 CD5 CD7 CD3 CD4 CD8 Stage
Viability
response to
IL-7
Proliferative
response to
IL-7
1 111122 III ND 1
2 111111 III 22
3 111211 II 11
4 111122 III 11
5 111122 III 11
6 2 ND 1112 III ND 2
7 111212 II 11
8 111211 II ND 1
9 1111 ND 1 III 22
10 111121 III 12
11 111121 III 12
12 ND 112 ND 2 II ND 1
13 111122 III 11
14 211112 III 11
15 211212 II ND 2
16 111221 II ND 1
17 111212 II 11
18 111111 III ND 1
19 111211 II 11
20 111112 III ND 1
21 111121 III ND 2
T-cellmaturationstagesweredeﬁnedasdescribed17:StageI(Pro-TL):CD71CD22CD52CD32;StageII(ImmatureTL):CD71(CD2and/orCD5)1CD32;StageIII(mature
TL): CD71 CD21 CD51 CD31.
IL-7 indicates interleukin-7; T-ALL, T-cell acute lymphoblastic leukemia; ND, not determined.
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whether up-regulation of bcl-2 was simply a correlative event or
whether it had a causative role in IL-7–mediated promotion of
viability of T-ALL cells, bcl-2 antisense oligonucleotides were
added during culture of T-ALL cells with IL-7. As shown in Table
2, coculture with Bcl-2 antisense oligonucleotides prevented
IL-7–mediated bcl-2 protein up-regulation and reversed IL-7–
mediated in vitro survival of T-ALL cells. These results indicate
that up-regulated bcl-2 had a critical functional signiﬁcance for the
IL-7–mediated promotion of viability of T-ALLcells.
IL-7 promotes cell cycle progression of T-ALL cells
As mentioned above, besides promotion of viability, IL-7/IL-7R–
mediated signals have a critical role in cell expansion at early
stages of T-cell differentiation.5,6,18 To determine whether, besides
increased survival, IL-7 might mediate clonal expansion of primary
T-ALL cells, we examined DNA synthesis following culture of
leukemic cells with either media or with IL-7. As shown in Figure
2Afor one representative case, in 14 of 21 tested patients, addition
of IL-7 resulted in increased DNA synthesis compared with media
alone, as determined by assessment of 3H-thymidine incorporation
at various time intervals of culture. The mean value of the
proliferation index among these 14 patients was 17.3 and the
median value was 8.5 (range, 2.8-78.8). In contrast to the response
of primary T-ALL cells to IL-7, no proliferation was observed
when primary peripheral blood T lymphocytes from healthy
volunteer donors were examined (data not shown). To examine
whether increased 3H-thymidine incorporation in IL-7 cultures was
only due to the higher percentage of viable T-ALL cells or,
alternatively, represented cell expansion, cell cycle analysis was
performed. Culture with IL-7 resulted in the increase of cells in the
S and G2/M phases of the cell cycle (Figure 2B), demonstrating
that IL-7 not only prevented apoptosis but also induced prolifera-
tion of primary T-ALLcells.
To conﬁrm that proliferating cells in the in vitro cultures were of
malignant origin and not of normal T cells contaminating the
sample, 2 approaches were undertaken. First, cycling cells at the
S1G2/M phases of the cell cycle were isolated by cell sorting and
examined by PCR using patient-speciﬁc primers for the detection
of a speciﬁc clonal TCR rearrangement identiﬁed at diagnosis.
Such speciﬁc rearrangements were identiﬁed in the cycling cells,
conﬁrming that these cells were of malignant origin and were
absent in cells from other patients or from healthy donors (Figure
2C). Second, for patients without speciﬁc rearrangements but with
low or negative CD3 expression, cells at the S1G2/M phases were
sorted after 72 hours of IL-7 culture, and absence of CD3
expressionwasassessedbyﬂowcytometry,usingpropidiumiodide
and FITC-conjugated anti-CD3. This immunophenotypic ﬁnding
of the cells undergoing cell cycle progression during culture with
IL-7 was identical to that of fresh leukemic cells at the time of
diagnosis (data not shown).Therefore, both approaches determined
that the proliferating cells during in vitro culture with IL-7 were of
T-ALLorigin.
IL-7 mediates up-regulation of cyclins and activation of
cdks in T-ALL cells
The transition from the G0/G1 to the S phase of the cell cycle is
affected by exogenous factors and is positively regulated by
Figure 1. IL-7 prevents apoptosis of T-ALL cells during in vitro culture. T-ALL
cells were cultured either in media alone or in the presence of IL-7. After 72 hours of
culture, cells were harvested and stained with annexin V and propidium iodide as
described in “Materials and methods,” and viability was determined by FACS
analysis. Results obtained from one representative patient are shown and were
similar to those observed in 10 of 12 patients studied.
Figure 2. IL-7 promotes cell cycle progression in T-ALL cells. (A) T-ALL cells
were cultured for 72 hours in media alone or in the presence of IL-7, and proliferation
was examined by thymidine incorporation. (B)At the same time interval IL-7–cultured
cells were isolated, and the percentage of cells at each phase of the cell cycle was
examined as described in “Materials and methods.” (C) Cells cycling in response to
IL-7 are of malignant origin.After culture with IL-7, cells at the S1G2/M phases of the
cell cycle were isolated by cell sorting and examined by RT-PCR by using
patient-speciﬁc primers for the detection of a speciﬁc clonal TCR rearrangement
identiﬁed at diagnosis. Results from one representative patient (P4) among 3 patients
studied are shown. Primers used were speciﬁc for patient P4 and generated a PCR
product from P4 (CS) but not from patient P2 (B1) or from normal T cells.
Table 2. Effect of bcl-2 antisense oligonucleotides on Bcl-2 protein
expression and IL-7–mediated promotion of viability in T-ALL cells
Percentage
of live cells
Bcl-2 protein
expression (mean
ﬂuorescence
intensity)
Media 34.21 6.96
IL-7 48.64 12.25
IL-7 and control oligonucleotide 51.83 14.26
IL-7 and bcl-2 antisense 34.08 5.01
T-cell acute lymphoblastic leukemia (T-ALL) cells were cultured with media, IL-7,
or IL-7 and Bcl-2 antisense or control oligonucleotides. Bcl-2 protein expression and
percentage of viable cells were examined in 6 patients, and results of one
representative experiment are shown. The effect of bcl-2 antisense oligonucleotide
was examined in 2 patients, and results of one experiment are shown.
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substrates including Rb.19 Inactivation of Rb because of its
phosphorylation results in release of E2F transcription factors,
thereby allowing them to initiate DNAbinding and transcription of
S-phase genes.20-22 To determine the molecular mechanism(s) by
which IL-7 mediated cell cycle progression of T-ALL cells, we
examined the expression of cyclins, the expression and activation
of cdks, and the expression of cdk inhibitors. IL-7 led to up-
regulation of cyclin D2 and cyclinAin a sequential manner. Cyclin
D2, which is an early G1 cyclin, peaked at 24 hours of culture,
whereas cyclinA, which is an S-phase cyclin, was maximal at later
time points of culture (Figure 3A).
IL-7 slightly increased expression of cdk2 and cdk4 and had no
effect on expression of cdk6 (Figure 3B). Importantly, in contrast to
the minimal effect on the expression of these cdks, IL-7 induced a
striking activation of cdk4 (data not shown) and cdk2 (Figure 3C)
as determined by in vitro kinase reaction. To determine the in vivo
signiﬁcance of these ﬁndings we examined the phosphorylation
status of endogenous Rb, which is one of the most critical
substrates of the enzymatic activity of cdks in vivo. Culture with
IL-7 resulted in hyperphosphorylation of Rb (Figure 3D), indicat-
ing that IL-7–induced cdk activation occurred in vivo.
IL-7 activates cdk2 and promotes cell cycle progression in
T-ALL cells because of down-regulation of cdk inhibitor p27kip1
The enzymatic activation of cdks is regulated by cdk inhibitors,
which include members of the kip/cip and the INK family. Because
IL-7 induced a dramatic increase in the enzymatic activity of the
cdks, despite the minimal effect in their protein expression, we
examined whether IL-7 inﬂuenced the expression of cdk inhibitors.
Among these cdk inhibitors, p21cip1, p16INK4a, and p27kip1 were
detected. p27kip1 was detected in all patients studied (6 of 6). In
contrast, p16INK4a was detected only in 1 patient and p21cip1 was
detected in 3 patients. When p16INK4a and p21cip1 were detectable,
they were up-regulated during culture with IL-7 (Figure 3E,F). In
contrast, p27kip1 was signiﬁcantly down-regulated during IL-7
culture in all cases (Figure 3E,F).
To determine whether down-regulation of p27kip1 had a caus-
ative role in IL-7–mediated cell cycle progression, 2 approaches
were undertaken: First, T-ALL cells were cultured with IL-7 in the
presence of rapamycin, which prevents down-regulation of endog-
enous p27kip1.23,24 Second, T-ALL cells were cultured with IL-7 in
the presence of VP22/p27kip1 fusion protein, which is capable of
translocating recombinant p27kip1 into the nucleus of cocultured
cells, thereby leading to forced sustained expression of p27kip1.16As
shown in Figure 4A, rapamycin, VP22/p27kip1 fusion protein, or
their combination signiﬁcantly inhibited IL-7–mediated cell cycle
progression and cellular proliferation. Moreover, VP22/p27kip1
fusion protein, but not VP22 control protein, inhibited IL-7–
induced cdk2 activation (Figure 4B). Consistent with the effects of
rapamycin and VP22/p27kip1 on cell cycle progression and cellular
proliferation (Figure 4A) and the effect of VP22/p27kip1 on cdk2
activation (Figure 4B), analysis of the phosphorylation status of
endogenous Rb revealed that rapamycin, VP22/p27kip1, or their
combination reversed hyperphosphorylation of Rb induced by IL-7
(Figure 4C). Thus, sustained increased expression of p27kip1
prevents IL-7–mediated cdk2 activation, DNA synthesis, and
progression through the cell cycle. These results strongly indicate
that down-regulation of p27kip1 has a causative role in IL-7–
mediatedactivationofcdk2,resultinginsubsequenthyperphospho-
rylation of Rb and cell cycle progression.
Down-regulation of p27kip1 is mandatory for induction of bcl-2
expression and promotion of viability by IL-7 in T-ALL cells
Propidium iodide staining for analysis of cell cycle progression
revealed that addition of rapamycin, VP22/p27kip1, or their combi-
nation not only diminished the ability of IL-7 to induce cell cycle
progression but also diminished the ability of IL-7 to promote
survival of T-ALLcells during culture (Figure 5A).
Figure 3. IL-7 mediates up-regulation of cyclins and activates cyclin-dependent
kinases due to down-regulation of cyclin dependent kinase inhibitor p27kip1 in
T-ALL cells. (A,B) T-ALLcells were cultured with IL-7 for the indicated time intervals,
lysates were analyzed by SDS-PAGE and immunoblotted with an antibody speciﬁc
for cyclin D2. Blots were stripped and reprobed sequentially with antibodies speciﬁc
for cyclin A, cdk6, cdk4, and cdk2. Representative results from 1 among 4 patients
studied are shown. (C) From the same samples immunoprecipitations were per-
formed with anti-cdk2–speciﬁc antiserum agarose conjugate and in vitro kinase
reactions were done by using Histone H1 as exogenous substrate. Reactions were
analyzed by 10% SDS-PAGE, transferred to PVDF membrane and exposed to x-ray
ﬁlm. (D) Lysates from the same samples were analyzed by 6% SDS-PAGE,
transferred on nitrocellulose membrane, and immunoblotted with mAb speciﬁc for
Rb. (E,F) Samples from 2 individual patients were cultured for various time intervals
in the presence of IL-7 and examined for the expression of p16INK4, p21cip1, and
p27kip1 by immunoblot. Representative results from 2 among 6 patients studied
are shown.
Figure 4. Effects of rapamycin and p27kip1. (A) Rapamycin and forced expression
of p27kip1 by VP22/p27kip1 fusion protein prevent IL-7–mediated increase of T-ALL
cells in the S1G2M phase and DNA synthesis. T-ALL cells were cultured with IL-7
either alone or in the presence of rapamycin, VP22/p27kip1 fusion protein, VP22
control protein, or the indicated combinations. Cultures were examined for percent-
age of cells at the S1G2M phases of the cell cycle and for DNA synthesis by
thymidine incorporation as described in Materials and methods. Representative
results from 1 among 3 patients studied are shown. (B) VP22/p27kip1 prevents
IL-7–mediated activation of cdk2. T-ALL cells were cultured for 72 hours under the
indicated conditions, and activation of cdk2 was determined in cell lysates by in vitro
kinase reactions by using Histone H1 as exogenous substrate. Reactions were
analyzed by SDS-PAGE, transferred to PVDF membrane, and exposed to x-ray ﬁlm.
(C)Rapamycin,VP22/p27kip1,andtheircombinationpreventIL-7–mediatedphosphor-
ylation of Rb. T-ALL cells were cultured for 72 hours under the indicated conditions,
analyzed by 6% SDS-PAGE, transferred on nitrocellulose membrane, and immuno-
blotted with mAb speciﬁc for Rb.
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regulating expression of bcl-2, we examined whether forced
sustained expression of p27kip1, which diminished the ability of
IL-7 to promote survival of T-ALL cells, affected expression of
bcl-2. As shown in Figure 5B, VP22/p27kip1 alone or in combina-
tion with rapamycin inhibited IL-7–induced up-regulation of bcl-2
protein expression as determined by ﬂow cytometry. These results
show that down-regulation of p27kip1 is mandatory not only for cell
cycle progression but also for up-regulation of bcl-2 expression and
promotion of viability of T-ALLcells in response to IL-7.
Discussion
IL-7 was initially identiﬁed and cloned on the basis of its ability to
induce proliferation of B-cell precursors in the absence of stromal
cells.25 However, IL-7 is also expressed in the thymus and has been
shown to stimulate the growth of immature double-negative and
mature single-positive thymocytes in thymic organ cultures.6,25-27
In addition, IL-7/IL-7R signaling plays a critical role in the
maintenance of the peripheral T-cell pool, because the few periph-
eral T cells seen in the IL-7R2/2 mice show impaired response to
both TCR-dependent and TCR-independent stimuli because of
decreased frequency and clonogenicity of T cells.2,18 In humans,
defective IL-7R expression results in T2B1natural killer1 severe
combined immunodeﬁciency.28,29 These data implicate that IL-7
plays a fundamental role at most stages of T-cell development.
Expression of IL-7R during T-cell ontogeny coincides with the
expression of bcl-2,30 and the lack of IL-7 signaling results in
reduction of endogenous bcl-2 levels both in thymocytes and in
mature T cells.18 Strikingly, the impaired functions of IL7R2/2 T
cells are normalized by the introduction of bcl-2 transgene.3,4
However, although the bcl-2 transgene rescued T cells from the
defects of IL-7 deﬁciency and allowed proliferative response to
T-cell mitogenic signals, bcl-2 itself does not stimulate prolifera-
tion and cannot substitute for signals generated during thymic
selection driven byTCR/major histocompatibility complex interac-
tion.4 Furthermore, expression of bcl-2 inhibits proliferation of
stimulated T cells.31-34 Therefore, although the IL-7/IL-7R system
plays a critical role in the maintenance of bcl-2 levels in developing
thymocytes and peripheral T cells, the mechanism by which IL-7
induces T-cell proliferation is not mediated by bcl-2. Our present
study shows that IL-7 directly mediates cell cycle progression and
proliferation on T-ALL cells by down-regulating the cdk inhibitor
p27kip1. p27kip1 regulates the G1-S transition by stoichiometric
inhibitionofcyclinE-cdk2holoenzyme.p27kip1alsobindstocyclin
D/cdk4 and cyclin D/cdk6 complexes and inhibits their activity,
whereas, in actively proliferating cells, p27kip1 is sequestered by
cyclin D-cdk4 complexes. This interaction helps ensure that
D-type cyclins and E-type cyclins are sequentially activated in
the G1 phase.35
Our present study shows that IL-7 mediates not only up-
regulation of bcl-2 and increased survival but also cell cycle
progression and proliferation of T-ALLcells. The key step required
for the induction of both increased viability and cell cycle
progression by IL-7 is the down-regulation of p27kip1 cdk inhibitor.
Down-regulation of p27kip1 temporally coincided with a dramatic
increase in the enzymatic activity of cdk4 and cdk2, hyperphospho-
rylation of Rb, and progression to the S phase of the cell cycle.
Down-regulation of p27kip1 was mandatory for IL-7–mediated cell
cycle progression, because rapamycin, which prevents p27kip1
down-regulation and forced expression of p27kip1 in T-ALL cells,
inhibited IL-7–mediated cdk2 activation, Rb hyperphosphoryla-
tion, and cell cycle progression. Moreover, rapamycin and forced
expression of p27kip1 also signiﬁcantly diminished the effect of
IL-7 on the promotion of viability by preventing IL-7–mediated
up-regulation of bcl-2, suggesting that IL-7–mediated survival is
achieved, at least in part, through down-regulation of p27kip1.
Extensive studies during the past few years provided compel-
ling evidence that p27kip1 has a critical role in carcinogenesis,
because p27kip1-deﬁcient and hemizygote mice develop spontane-
ous tumors.36 Moreover, in human tumors the levels of p27kip1
protein strongly correlate with prognosis and are controlled by
posttranscriptional mechanisms that regulate protein expression in
the absence of p27kip1 gene mutation.37,38 Our present studies show
that IL-7 induced proliferation of T-ALL cells by down-regulating
p27kip1 protein levels and support the notion that p27kip1 might
function as a tumor suppressor gene not only because it works as a
negative regulator of cell cycle progression but also because it is
associated with induction of apoptosis. Studies on IL-7 transgenic
mice have shown that IL-7 perturbs thymic T-cell development and
leads to the absence of CD32CD41CD81 double-positive thymo-
cytes, resulting in a remarkable increase in the percentage of
single-positive CD31CD41 or CD31CD81 thymocytes, a pheno-
type very rare among normal thymocytes. Moreover, IL-7 trans-
gene promotes malignant transformation of lymphocytes, resulting
in the development of lymphomas.1 On the basis of these ﬁndings it
has been suggested that, as a biologic effector, IL-7 not only
perturbs the development of lymphoid cells but also promotes the
growth of such populations at risk for malignant transformation.1
Importantly,IL-7isproducedbybonemarrowandthymicstroma.25
Therefore, it is present in the microenvironments in which the
Figure 5. Down-regulation of p27kip1 is mandatory for induction of bcl-2
expression and promotion of viability by IL-7 in T-ALL cells. (A) T-ALLcells were
cultured for 72 hours under the indicated conditions, and the percentage of viable
cells was examined by propidium iodide staining followed by FACS analysis as
described in Materials and methods. (B) T-ALL cells isolated from the indicated
culture conditions were examined for viability as above and for expression of bcl-2
protein levels by intracellular staining and by FACS analysis, as described in
Materials and methods.
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acquisition of selective growth advantage of the leukemic cells.
Although the molecular pathways of cytokine signaling and
their inﬂuence on viability and malignant transformation are poorly
understood, the early signaling events triggered by engagement of
the IL-7Rs are directly linked to activation of protein tyrosine
kinase activity, protein tyrosine phosphorylation, activation of
phosphatidylinositol 3-kinase (PI-3K), and inositol phospholipid
turnover in human fetal thymocytes and T-lineage ALL blasts.39,40
PI-3K is involved in the regulation of the Forkhead family of
transcription factors,41 whereas IL-7R ligation directly activates
Jak kinases and transcription factors of the STAT family, most
notably STAT5.40 Although most studies have shown that p27kip1
expression is mainly regulated at the posttranscriptional level by
controlling degradation of this protein,42-44 a small number of
studies have proposed that p27kip1 may also be regulated at the
transcriptional level.45,46 Interestingly, the later study has also
implicated the increased expression of p27kip1 in the induction of
cell death.46 This mechanism involves PI-3K–mediated activation
of Forkhead transcription factors, which become phosphorylated
and function as repressors of p27kip1 transcription. However, STAT
proteins regulate p27kip1 expression at a posttranscriptional level,
and the decrease of p27kip1 abundance correlates with the ability of
cytokines to induce both progression from G1 to the S phase of the
cell cycle and malignant transformation.47
There is extensive evidence that during the G1-S transition
p27kip1 protein levels change dramatically because of ubiquitin-
targeted degradation of p27kip1 by the 26S proteasome.43 Like other
G1-S regulatory proteins, p27kip1 must undergo phosphorylation on
Thr187, which lies within the cdk/mitogen-activated protein kinase
(MAPK) consensus site, to be targeted by the ubiquitin ligase
complex.48 Cyclin/cdk holoenzymes can phosphorylate this resi-
due, and it has been proposed that cyclin E/cdk2 performs this
function in vivo.49 Other studies support a critical role of Ras and
the MAPK in the phosphorylation of p27kip1.50 IL-7 is known to
mediate active signaling events by Jak family kinases that are
linked to the IL-7R as well as by PI-3K, subsequently leading to
Ras/MAPK activation.51 Therefore, IL-7 may regulate direct
phosphorylationandubiquitinationofp27kip1,leadingtoitsassocia-
tion with other regulatory components of the ubiquitination com-
plex, a process required for subsequent degradation of p27kip1.
Further studies will be required to elucidate the role of each one
of these signaling pathways in IL-7–mediated survival and prolif-
eration of T-ALL cells. Such studies will determine whether these
pathways are equally involved in IL-7–induced down-regulation of
p27kip1 and up-regulation of bcl-2 or whether each pathway has a
selective or predominant role in regulating these 2 downstream
molecular events. Regardless of the mechanism, our results show
for the ﬁrst time that a causative link between IL-7–mediated
proliferation and p27kip1 down-regulation exists in malignant T
cells. More importantly, sustained increase of p27kip1 expression in
T-ALL cells not only prevents their proliferation but also promotes
apoptosis by preventing IL-7–mediated up-regulation of bcl-2.
Further understanding of the mechanisms involved in this process
could lead to improved therapeutic strategies aimed at achieving
high levels of p27kip1 expression in T-ALL blasts, perhaps with a
gene therapy approach or by the use of cdk inhibitors that are
currently being broadly developed.52
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